SLN.L Regulatory News (SLN)

Silence Therapeutics plc ("Silence" or the "Company")

Appointment of Chief Medical Officer

Silence Therapeutics plc has appointed Michael Khan its Chief Medical Officer to oversee the company's programme of Phase II clinical trials which are scheduled to start later this year.

Dr Khan became Chief Medical Adviser and a director of the company in September 2012. In his new role he will actively help develop and expand the Silence Therapeutics clinical pipelines in oncology, and acute lung injury, amongst others.

He is an Associate Professor of Medicine at the University of Warwick, a Consultant Physician and Endocrinologist at University Hospitals of Coventry and Warwickshire and Director of the Warwickshire FH and Coronary Prevention Service. He has a strong track record in cancer research and is an editor and co-author of one of the standard textbooks in the field, the Molecular Biology of Cancer.

In recognition of his new commitment, the company will pay an increased consultancy.

Mike said: "These are very exciting times for Silence Therapeutics, with one oncology drug advancing to Phase II. Moreover, with a range of new indications in the pipeline, I am really happy to be a part of this dynamic new enterprise".

Ali Mortazavi, director of Corporate Strategy said: 'I'm delighted Mike has decided to devote more time to us. Next year will be pivotal for Silence after so many years spent preparing for Phase II trials.'